Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR8554 + SHR0410
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
SHR8554 + SHR0410 is a combination of two investigational drugs developed for the management of acute postoperative pain, particularly following abdominal or orthopedic surgery. SHR8554, also known as tegileridine and marketed in China under the brand name Asut, is an intravenously administered μ-opioid receptor agonist with G protein-coupling bias, designed to provide potent analgesia while reducing side effects such as respiratory depression and gastrointestinal inhibition. SHR0410 is another investigational analgesic agent; while its precise mechanism has not been explicitly detailed in public sources, it is being studied in combination with tegileridine for enhanced pain control after surgery. The combination aims to improve analgesic efficacy compared to monotherapy with either agent alone. Both drugs are developed by Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company[1][2][5][7].
- Brand names
- Asut (for SHR8554)
- Other names
- tegileridine (for SHR8554)Riminkefon (for SHR0410)
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on SHR8554 + SHR0410.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR8554 + SHR0410.